Silence Therapeutics plc (NASDAQ:SLN) Short Interest Update

Silence Therapeutics plc (NASDAQ:SLN - Get Free Report) saw a significant drop in short interest in May. As of May 15th, there was short interest totalling 1,250,000 shares, a drop of 15.0% from the April 30th total of 1,470,000 shares. Approximately 4.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 228,700 shares, the days-to-cover ratio is presently 5.5 days.

Analyst Upgrades and Downgrades

A number of analysts have commented on SLN shares. Morgan Stanley lowered their target price on shares of Silence Therapeutics from $45.00 to $25.00 and set an "overweight" rating for the company in a report on Friday, May 9th. The Goldman Sachs Group reduced their price target on Silence Therapeutics from $4.00 to $3.00 and set a "sell" rating on the stock in a research report on Friday, May 9th. BMO Capital Markets dropped their price objective on Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating for the company in a report on Tuesday, March 4th. Chardan Capital cut their target price on Silence Therapeutics from $55.00 to $35.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Finally, HC Wainwright restated a "buy" rating and set a $75.00 target price on shares of Silence Therapeutics in a research report on Friday, March 7th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $33.83.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Barclays PLC increased its position in shares of Silence Therapeutics by 83.8% in the fourth quarter. Barclays PLC now owns 6,126 shares of the company's stock worth $42,000 after purchasing an additional 2,793 shares during the last quarter. JPMorgan Chase & Co. purchased a new stake in shares of Silence Therapeutics during the 4th quarter valued at $26,000. Virtus ETF Advisers LLC raised its position in shares of Silence Therapeutics by 130.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company's stock valued at $74,000 after buying an additional 6,098 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in shares of Silence Therapeutics during the 4th quarter worth $69,000. Finally, Two Sigma Advisers LP grew its position in Silence Therapeutics by 18.6% in the fourth quarter. Two Sigma Advisers LP now owns 98,800 shares of the company's stock worth $680,000 after acquiring an additional 15,500 shares in the last quarter. Institutional investors own 98.73% of the company's stock.

Silence Therapeutics Trading Down 1.6%

NASDAQ SLN traded down $0.09 during trading hours on Thursday, hitting $5.41. 100,189 shares of the company's stock were exchanged, compared to its average volume of 302,130. Silence Therapeutics has a 1-year low of $1.97 and a 1-year high of $22.47. The firm has a market cap of $161.92 million, a price-to-earnings ratio of -3.45 and a beta of 1.41. The stock has a 50-day simple moving average of $3.74 and a 200 day simple moving average of $5.07.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.42). Silence Therapeutics had a negative return on equity of 62.81% and a negative net margin of 342.00%. The business had revenue of $0.14 million for the quarter, compared to analyst estimates of $3.58 million. On average, sell-side analysts anticipate that Silence Therapeutics will post -1.77 earnings per share for the current fiscal year.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.